Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

PPIs Get AHRQ Stamp Of Approval Vs. Surgery; Generics Could Be Big Winners

Executive Summary

The Agency for Healthcare Research & Quality's study on the effectiveness of proton pump inhibitors could lead to more difficulties for brand companies in seeking formulary placement

You may also be interested in...



Celebrex Shows “Overall Net Benefit” Versus NSAIDs, AHRQ Draft Report Says

The safety benefit of Pfizer's COX-2 inhibitor Celebrex compared to non-selective nonsteroidal anti-inflammatory drugs is affirmed in a draft report from the Agency for Healthcare Research & Quality on osteoarthritis treatments

AHRQ Comparative Effectiveness Reviews Will Expand Beyond Medicare

The Agency for Healthcare Research & Quality is preparing to expand the scope of its comparative effectiveness reviews beyond the Medicare population

AHRQ Comparative Effectiveness Reviews Will Expand Beyond Medicare

The Agency for Healthcare Research & Quality is preparing to expand the scope of its comparative effectiveness reviews beyond the Medicare population

Related Content

Topics

UsernamePublicRestriction

Register

LL005491

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel